Per Clinical Protocol No.516 "Chronic viral hepatitis C", 2021
Chronic viral hepatitis C therapy — calculateur en ligne | DOZATOR
Select an option
Patient with any HCV genotype without prior antiviral therapy experience (naive)
Patient with any HCV genotype who did not respond to prior therapy with pegylated interferon plus ribavirin and/or sofosbuvir plus ribavirin
Patient with any HCV genotype who did not respond to prior therapy with NS3/4A inhibitors (glecaprevir, grazoprevir, narlaprevir, paritaprevir), including in combination with NS5B inhibitors (dasabuvir, sofosbuvir)
Patient with any HCV genotype who did not respond to prior therapy with NS5A inhibitors (velpatasvir, daclatasvir, ledipasvir, ombitasvir, pibrentasvir, elbasvir)
Patient who did not respond to prior therapy with both NS5A inhibitors and NS3/4A inhibitors
Additionally: for patients with genotype 1 without cirrhosis or with compensated cirrhosis after ineffective antiviral therapy with NS3/4A inhibitors, without NS5A inhibitors
Additionally: for patients with genotype 1 without cirrhosis or with compensated cirrhosis after ineffective antiviral therapy with NS5A inhibitors, without NS3/4A inhibitors